Anti-EMA [E29] recombinant antibody
Invented at University of Oxford
- Datasheet
- References (19)
- Inventor Info
Info
| Catalogue Number | 154822 |
| Applications | N/A |
| Antigen/Gene or Protein Targets | Epithelial Membrane Antigen (EMA) |
| Reactivity | Human |
| Relevance |
Recombinant monoclonal antibody used as a pan-epithelial marker to categorise cancers of epithelial origin and detect metastatic loci. Background and Research Application Glycoproteins isolated from human milk fat globule membranes, designated epithelial membrane antigen (EMA), have been detected immunohistochemically in most nonneoplastic epithelia and are potentially a highly effective marker for establishing the epithelial nature of neoplastic cells. This is a recombinant version of the anti-EMA monoclonal antibody . Anti-EMA was created for use in diagnostic immunocytochemistry for identification of tumours of epithelial origins. EMA is present within membranes of the apical side of secretory epithelia, and is typically overexpressed in colon, breast, ovarian, lung and pancreatic cancers. |
| Host | Mouse |
| Immunogen | Human milk fat globule membrane preparation |
| Subclass | IgG2a |
| Research Area | Cancer, Cell Type or Organelle Marker, Cell Signaling & Signal Transduction |
| Immunogen UniProt ID | P15941 |
| Notes |
Production Details Purified using multi-step affinity chromatography with protein A. Storage Conditions Store at -20 degrees frozen. Avoid repeated freeze/thaw cycles. Points of Interest Anti-EMA (E29) reacts with a wide variety of human epithelia and mesothelial cells but is unreactive with other cell types (bar the occasional plasma cell). It can detect neoplastic cells in bone marrow smears where they cannot be identified by routine procedure and reacts with a wide variety of neoplastic epithelia and neoplastic mesothelial cells. Anti-EMA can be used to help distinguish mesothelioma, which can be difficult to differentiate from adenocarcinoma, and has been shown to react strongly with neoplastic plasma cells from a case of multiple myeloma, helping with tumour identification. Anti-EMA can help of detect micro-metastases in breast cancer patients in which the tumour was undetectable in routine histological examination. It is a highly valuable antibody when combined with leukocyte-associated antigens monoclonal antibodies as it allows for the majority of anaplastic tumours to be classified as lymphoma or carcinoma. Anti-EMA reacts with equal intensity to both cryostat and paraffin embedded tissue sections. Concentration 1mg/ml as standard |
References: 19 entries
A case of a CD56-expressing ectomesenchymal chondromyxoid tumor of the tongue: potential diagnostic usefulness of commonly available CD56 over CD57
A new monoclonal antibody to epithelial membrane antigen (EMA)-E29. A comparison of its immunocytochemical reactivity with polyclonal anti-EMA antibodies and with another monoclonal antibody, HMFG-2.
Ando et al. 2015. Head Neck. :. PMID: 25782598.
Cordell et al. 1985. Br J Cancer. 52(3):347-54. PMID: 3899155.
Genome-wide transcript profiling reveals novel breast cancer-associated intronic sense RNAs.
Habougit et al. 2015. Int J Surg Pathol. :. PMID: 26113666.
Heyderman et al. 1985. Br J Cancer. 52(3):355-61. PMID: 3899156.
Invasive micropapillary mucinous carcinoma of the breast is associated with poor prognosis.
Kim et al. 2015. PLoS One. 10(3):e0120296. PMID: 25798919.
Liu et al. 2015. Breast Cancer Res Treat. 151(2):443-51. PMID: 25953688.
Maxillary carcinosarcoma: Identification of a novel MET mutation in both carcinomatous and sarcomatous components through next generation sequencing.
Mediastinal Mature Teratoma With Malignant Carcinomatous Transformation (Somatic-Type Malignancy) With Metastatic Course.
MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only partly hypoglycosylated form.
Ohlmann et al. 2015. Ann Diagn Pathol. :. PMID: 25990776.
Production of monoclonal antibodies against human epithelial membrane antigen for use in diagnostic immunocytochemistry.
Sclerosing epithelioid fibrosarcoma of the kidney: clinicopathologic and molecular study of a rare neoplasm at a novel location.
ten Berge et al. 2001. J Clin Pathol. 54(12):933-9. PMID: 11729213.
Tissue factor-bearing microparticles and CA19.9: two players in pancreatic cancer-associated thrombosis?
Woei-A-Jin et al. 2016. Br J Cancer. :. PMID: 27404454.
Add a reference
References: 19 entries
A case of a CD56-expressing ectomesenchymal chondromyxoid tumor of the tongue: potential diagnostic usefulness of commonly available CD56 over CD57
A new monoclonal antibody to epithelial membrane antigen (EMA)-E29. A comparison of its immunocytochemical reactivity with polyclonal anti-EMA antibodies and with another monoclonal antibody, HMFG-2.
Ando et al. 2015. Head Neck. :. PMID: 25782598.
Cordell et al. 1985. Br J Cancer. 52(3):347-54. PMID: 3899155.
Genome-wide transcript profiling reveals novel breast cancer-associated intronic sense RNAs.
Habougit et al. 2015. Int J Surg Pathol. :. PMID: 26113666.
Heyderman et al. 1985. Br J Cancer. 52(3):355-61. PMID: 3899156.
Invasive micropapillary mucinous carcinoma of the breast is associated with poor prognosis.
Kim et al. 2015. PLoS One. 10(3):e0120296. PMID: 25798919.
Liu et al. 2015. Breast Cancer Res Treat. 151(2):443-51. PMID: 25953688.
Maxillary carcinosarcoma: Identification of a novel MET mutation in both carcinomatous and sarcomatous components through next generation sequencing.
Mediastinal Mature Teratoma With Malignant Carcinomatous Transformation (Somatic-Type Malignancy) With Metastatic Course.
MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only partly hypoglycosylated form.
Ohlmann et al. 2015. Ann Diagn Pathol. :. PMID: 25990776.
Production of monoclonal antibodies against human epithelial membrane antigen for use in diagnostic immunocytochemistry.
Sclerosing epithelioid fibrosarcoma of the kidney: clinicopathologic and molecular study of a rare neoplasm at a novel location.
ten Berge et al. 2001. J Clin Pathol. 54(12):933-9. PMID: 11729213.
Tissue factor-bearing microparticles and CA19.9: two players in pancreatic cancer-associated thrombosis?
Woei-A-Jin et al. 2016. Br J Cancer. :. PMID: 27404454.
Add a reference
